Cargando…

Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy

BACKGROUND: Improvement of efficacy of immune checkpoint blockade (ICB) remains a major clinical goal. Association of ICB with immunomodulatory epigenetic drugs is an option. However, epigenetic inhibitors show a heterogeneous landscape of activities. Analysis of transcriptional programs induced in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anichini, Andrea, Molla, Alessandra, Nicolini, Gabriella, Perotti, Valentina Eleonora, Sgambelluri, Francesco, Covre, Alessia, Fazio, Carolina, Lofiego, Maria Fortunata, Di Giacomo, Anna Maria, Coral, Sandra, Manca, Antonella, Sini, Maria Cristina, Pisano, Marina, Noviello, Teresa, Caruso, Francesca, Brich, Silvia, Pruneri, Giancarlo, Maurichi, Andrea, Santinami, Mario, Ceccarelli, Michele, Palmieri, Giuseppe, Maio, Michele, Mortarini, Roberta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670381/ https://www.ncbi.nlm.nih.gov/pubmed/36397155 http://dx.doi.org/10.1186/s13046-022-02529-5

Ejemplares similares

Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial
por: Noviello, Teresa Maria Rosaria, et al.
Publicado: (2023)

An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells
por: Perotti, Valentina, et al.
Publicado: (2019)

Correction to: NFATc2 is an intrinsic regulator of melanoma dedifferentiation
por: Perotti, V., et al.
Publicado: (2019)

Immune Escape Mechanisms in Non Small Cell Lung Cancer
por: Anichini, Andrea, et al.
Publicado: (2020)

Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy
por: Lofiego, Maria Fortunata, et al.
Publicado: (2021)

Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy
por: Fazio, Carolina, et al.
Publicado: (2018)

Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival
por: Chiarucci, Carla, et al.
Publicado: (2020)

A novel microRNA signature for the detection of melanoma by liquid biopsy
por: Sabato, Claudia, et al.
Publicado: (2022)

Immunotherapy of brain metastases: breaking a “dogma”
por: Di Giacomo, Anna Maria, et al.
Publicado: (2019)

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade
por: Penna, Ilaria, et al.
Publicado: (2015)

Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells
por: Fucà, Giovanni, et al.
Publicado: (2021)

Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma
por: Minna, Emanuela, et al.
Publicado: (2020)

Gut Microbiota, Metabolome, and Body Composition Signatures of Response to Therapy in Patients with Advanced Melanoma
por: Vandoni, Giulia, et al.
Publicado: (2023)

Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma
por: Torchio, Martina, et al.
Publicado: (2021)

Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma
por: Grazia, G, et al.
Publicado: (2014)

Deep learning predicts short non-coding RNA functions from only raw sequence data
por: Noviello, Teresa Maria Rosaria, et al.
Publicado: (2020)

SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines
por: Di Giacomo, Anna M., et al.
Publicado: (2022)

Sema6A and Mical1 control cell growth and survival of BRAF(V600E) human melanoma cells
por: Loria, Rossella, et al.
Publicado: (2014)

PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
por: Lo Russo, G., et al.
Publicado: (2022)

An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions
por: Anichini, Andrea, et al.
Publicado: (1999)

Enrichment of KIR+CD57+ highly cytotoxic NK cells in sentinel lymph nodes of melanoma patients
por: Ali, Talib Hassan, et al.
Publicado: (2014)

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
por: Lo Russo, Giuseppe, et al.
Publicado: (2023)

Are Molecular Alterations Linked to Genetic Instability Worth to Be Included as Biomarkers for Directing or Excluding Melanoma Patients to Immunotherapy?
por: Palmieri, Giuseppe, et al.
Publicado: (2021)

Enrichment of CD56(dim)KIR+CD57+ highly cytotoxic NK cells in tumor infiltrated lymph nodes of melanoma patients
por: Ali, Talib Hassan, et al.
Publicado: (2014)

Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review)
por: GRAZIA, GIULIA, et al.
Publicado: (2014)

Structural Model for Recruitment of RIT1 to the LZTR1 E3 Ligase: Evidences from an Integrated Computational Approach
por: Paladino, Antonella, et al.
Publicado: (2021)

KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors
por: Palomba, Grazia, et al.
Publicado: (2020)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study
por: Calabrò, Luana, et al.
Publicado: (2021)

Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix
por: Di Giacomo, Anna M., et al.
Publicado: (2021)

Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles
por: Tringali, Cristina, et al.
Publicado: (2014)

Immunomodulatory activity of SGI-110: a basis for novel chemo-immunotherapeutic combinations in cancer treatment
por: Covre, Alessia, et al.
Publicado: (2013)

Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study
por: Paliogiannis, Panagiotis, et al.
Publicado: (2022)

Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma
por: Casula, Milena, et al.
Publicado: (2023)

microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response
por: Vallacchi, Viviana, et al.
Publicado: (2016)

Mammary-like adenocarcinoma of the vulva: a rare case report with next generation sequencing
por: Lobrano, Renato, et al.
Publicado: (2023)

Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach
por: Manca, Antonella, et al.
Publicado: (2019)

Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2023)

A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification
por: Dugo, Matteo, et al.
Publicado: (2015)

Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients
por: Colombino, Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_beh0mtjpg0o5lo48kvbgbe62l4